-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US28622K1043 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 3M |
|---|---|
| Target Price | None |
| Beta | nan |
| PE Ratio | None |
| Dividend Yield | None |
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ELAB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025